Hélène Ruffieux

Hélène Ruffieux

Auto-generated profile, based on publicly available information

Hélène Ruffieux

MRC Biostatistics Unit University of Cambridge

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Immunity
Verified
Journal Article
Open access
LBLaura Bergamaschi
Laura Bergamaschi
FMFederica Mescia
Federica Mescia
LTLorinda Turner
Lorinda Turner
AHAimee L. Hanson
Aimee L. Hanson
PKPrasanti Kotagiri
Prasanti Kotagiri
KSKenneth G.C. Smith
Kenneth G.C. Smith
The kinetics of the immune changes in COVID-19 across severity groups have not been rigorously assessed. Using immunophenotyping, RNA sequencing and serum cytokine analysis, we analyzed serial samples from 207 SARS-CoV2-infected individuals with a range of disease severities over 12 weeks from symptom onset. An early robust bystander CD8+ T cell immune response, without systemic inflammation, characterized asymptomatic or mild disease. Hospitalized individuals had delayed bystander responses and systemic inflammation that was already evident near symptom onset, indicating that immunopathology may be inevitable in some individuals. Viral load did not correlate with this early pathological response, but did correlate with subsequent disease severity. Immune recovery is complex, with profound persistent cellular abnormalities in severe disease correlating with altered inflammatory responses, with signatures associated with increased oxidative phosphorylation replacing those driven by cytokines tumor necrosis factor (TNF) and interleukin (IL)-6. These late immunometabolic and immune defects may have clinical implications.

1 March 2024 in Nature Immunology
Verified
Journal Article
Open access
PDF file
AHAimee L. Hanson
Aimee L. Hanson
MMMatthew P. Mulè
Matthew P. Mulè
HRHélène Ruffieux
Hélène Ruffieux
FMFederica Mescia
Federica Mescia
LBLaura Bergamaschi
Laura Bergamaschi
KSKenneth G. C. Smith
Kenneth G. C. Smith
Persistent symptoms following SARS-CoV-2 infection are increasingly reported, although the drivers of post-acute sequelae (PASC) of COVID-19 are unclear. Here we assessed 214 individuals infected with SARS-CoV-2, with varying disease severity, for one year from COVID-19 symptom onset to determine the early correlates of PASC. A multivariate signature detected beyond two weeks of disease, encompassing unresolving inflammation, anemia, low serum iron, altered iron-homeostasis gene expression and emerging stress erythropoiesis; differentiated those who reported PASC months later, irrespective of COVID-19 severity. A whole-blood heme-metabolism signature, enriched in hospitalized patients at month 1–3 post onset, coincided with pronounced iron-deficient reticulocytosis. Lymphopenia and low numbers of dendritic cells persisted in those with PASC, and single-cell analysis reported iron maldistribution, suggesting monocyte iron loading and increased iron demand in proliferating lymphocytes. Thus, defects in iron homeostasis, dysregulated erythropoiesis and immune dysfunction due to COVID-19 possibly contribute to inefficient oxygen transport, inflammatory disequilibrium and persisting symptomatology, and may be therapeutically tractable.

1 October 2021 in Science Immunology
Verified
Journal Article
Closed access
RWRobert A. Watson
Robert A. Watson
OTOrion Tong
Orion Tong
RCRosalin Cooper
Rosalin Cooper
CTChelsea A. Taylor
Chelsea A. Taylor
PSPiyush K. Sharma
Piyush K. Sharma
BFBenjamin P. Fairfax
Benjamin P. Fairfax
The cytotoxicity and clone size of CD8 + T cell pretreatment are prognostic for immune checkpoint blockade.

30 January 2023 in Nature Immunology
Verified
Journal Article
Open access
PDF file
HRHélène Ruffieux
Hélène Ruffieux
AHAimee L. Hanson
Aimee L. Hanson
SLSamantha Lodge
Samantha Lodge
NLNathan G Lawler
Nathan G Lawler
LWLuke Whiley
Luke Whiley
CHChristoph Hess
Christoph Hess
The biology driving individual patient responses to severe acute respiratory syndrome coronavirus 2 infection remains ill understood. Here, we developed a patient-centric framework leveraging detailed longitudinal phenotyping data and covering a year after disease onset, from 215 infected individuals with differing disease severities. Our analyses revealed distinct ‘systemic recovery’ profiles, with specific progression and resolution of the inflammatory, immune cell, metabolic and clinical responses. In particular, we found a strong inter-patient and intra-patient temporal covariation of innate immune cell numbers, kynurenine metabolites and lipid metabolites, which highlighted candidate immunologic and metabolic pathways influencing the restoration of homeostasis, the risk of death and that of long COVID. Based on these data, we identified a composite signature predictive of systemic recovery, using a joint model on cellular and molecular parameters measured soon after disease onset. New predictions can be generated using the online tool http://shiny.mrc-bsu.cam.ac.uk/apps/covid-19-systemic-recovery-prediction-app, designed to test our findings prospectively.

3 June 2020 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
HRHélène Ruffieux
Hélène Ruffieux
JCJérôme Carayol
Jérôme Carayol
RPRadu Popescu
Radu Popescu
MHMary-Ellen Harper
Mary-Ellen Harper
RDRobert Dent
Robert Dent
AVArmand Valsesia
Armand Valsesia
Molecular quantitative trait locus (QTL) analyses are increasingly popular to explore the genetic architecture of complex traits, but existing studies do not leverage shared regulatory patterns and suffer from a large multiplicity burden, which hampers the detection of weak signals such as trans associations. Here, we present a fully multivariate proteomic QTL (pQTL) analysis performed with our recently proposed Bayesian method LOCUS on data from two clinical cohorts, with plasma protein levels quantified by mass-spectrometry and aptamer-based assays. Our two-stage study identifies 136 pQTL associations in the first cohort, of which >80% replicate in the second independent cohort and have significant enrichment with functional genomic elements and disease risk loci. Moreover, 78% of the pQTLs whose protein abundance was quantified by both proteomic techniques are confirmed across assays. Our thorough comparisons with standard univariate QTL mapping on (1) these data and (2) synthetic data emulating the real data show how LOCUS borrows strength across correlated protein levels and markers on a genome-wide scale to effectively increase statistical power. Notably, 15% of the pQTLs uncovered by LOCUS would be missed by the univariate approach, including several trans and pleiotropic hits with successful independent validation. Finally, the analysis of extensive clinical data from the two cohorts indicates that the genetically-driven proteins identified by LOCUS are enriched in associations with low-grade inflammation, insulin resistance and dyslipidemia and might therefore act as endophenotypes for metabolic diseases. While considerations on the clinical role of the pQTLs are beyond the scope of our work, these findings generate useful hypotheses to be explored in future research; all results are accessible online from our searchable database. Thanks to its efficient variational Bayes implementation, LOCUS can analyse jointly thousands of traits and millions of markers. Its applicability goes beyond pQTL studies, opening new perspectives for large-scale genome-wide association and QTL analyses. Diet, Obesity and Genes (DiOGenes) trial registration number: NCT00390637. Exploring the functional mechanisms between the genotype and disease endpoints in view of identifying innovative therapeutic targets has prompted molecular quantitative trait locus studies, which assess how genetic variants (single nucleotide polymorphisms, SNPs) affect intermediate gene (eQTL), protein (pQTL) or metabolite (mQTL) levels. However, conventional univariate screening approaches do not account for local dependencies and association structures shared by multiple molecular levels and markers. Conversely, the current joint modelling approaches are restricted to small datasets by computational constraints. We illustrate and exploit the advantages of our recently introduced Bayesian framework LOCUS in a fully multivariate pQTL study, with ≈300K tag SNPs (capturing information from 4M markers) and 100 − 1, 000 plasma protein levels measured by two distinct technologies. LOCUS identifies novel pQTLs that replicate in an independent cohort, confirms signals documented in studies 2 − 18 times larger, and detects more pQTLs than a conventional two-stage univariate analysis of our datasets. Moreover, some of these pQTLs might be of biomedical relevance and would therefore deserve dedicated investigation. Our extensive numerical experiments on these data and on simulated data demonstrate that the increased statistical power of LOCUS over standard approaches is largely attributable to its ability to exploit shared information across outcomes while efficiently accounting for the genetic correlation structures at a genome-wide level.

16 March 2017 in Biostatistics
Verified
Journal Article
Open access
PDF file
HRHelene Ruffieux
Helene Ruffieux
ADAnthony C. Davison
Anthony C. Davison
JHJorg Hager
Jorg Hager
IIIrina Irincheeva
Irina Irincheeva
Combined inference for heterogeneous high-dimensional data is critical in modern biology, where clinical and various kinds of molecular data may be available from a single study. Classical genetic association studies regress a single clinical outcome on many genetic variants one by one, but there is an increasing demand for joint analysis of many molecular outcomes and genetic variants in order to unravel functional interactions. Unfortunately, most existing approaches to joint modeling are either too simplistic to be powerful or are impracticable for computational reasons. Inspired by Richardson and others (2010, Bayesian Statistics 9), we consider a sparse multivariate regression model that allows simultaneous selection of predictors and associated responses. As Markov chain Monte Carlo (MCMC) inference on such models can be prohibitively slow when the number of genetic variants exceeds a few thousand, we propose a variational inference approach which produces posterior information very close to that of MCMC inference, at a much reduced computational cost. Extensive numerical experiments show that our approach outperforms popular variable selection methods and tailored Bayesian procedures, dealing within hours with problems involving hundreds of thousands of genetic variants and tens to hundreds of clinical or molecular outcomes.